相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Activation of insulin-like growth factor-1 receptor confers acquired resistance to osimertinib in non-small cell lung cancer with EGFR T790M mutation
Daisuke Hayakawa et al.
THORACIC CANCER (2020)
FOXM1: a potential therapeutic target in human solid cancers
Soheila Borhani et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2020)
Targeting HER3, a Catalytically Defective Receptor Tyrosine Kinase, Prevents Resistance of Lung Cancer to a Third-Generation EGFR Kinase Inhibitor
Donatella Romaniello et al.
CANCERS (2020)
UTAP: User-friendly Transcriptome Analysis Pipeline
Refael Kohen et al.
BMC BIOINFORMATICS (2019)
The NCATS BioPlanet - An Integrated Platform for Exploring the Universe of Cellular Signaling Pathways for Toxicology, Systems Biology, and Chemical Genomics
Ruili Huang et al.
FRONTIERS IN PHARMACOLOGY (2019)
EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer
K. Hastings et al.
ANNALS OF ONCOLOGY (2019)
First- and Second-Generation EGFR-TKIs Are All Replaced to Osimertinib in Chemo-Naive EGFR Mutation-Positive Non-Small Cell Lung Cancer?
Masayuki Takeda et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer
Khyati N. Shah et al.
NATURE MEDICINE (2019)
FoxM1 promotes epithelial-mesenchymal transition, invasion, and migration of tongue squamous cell carcinoma cells through a c-Met/AKT-dependent positive feedback loop
Huiling Yang et al.
ANTI-CANCER DRUGS (2018)
A Combination of Approved Antibodies Overcomes Resistance of Lung Cancer to Osimertinib by Blocking Bypass Pathways
Donatella Romaniello et al.
CLINICAL CANCER RESEARCH (2018)
Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer
Suresh S. Ramalingam et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer
J. -C. Soria et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Antibody-assisted target identification reveals afatinib, an EGFR covalent inhibitor, down-regulating ribonucleotide reductase
Cheng-Han Yu et al.
Oncotarget (2018)
Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: an observational study
Maximilian J. Hochmair et al.
FUTURE ONCOLOGY (2018)
An oligoclonal antibody durably overcomes resistance of lung cancer to third-generation EGFR inhibitors
Maicol Mancini et al.
EMBO MOLECULAR MEDICINE (2018)
Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer
T. S. Mok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
The receptor tyrosine kinase AXL mediates nuclear translocation of the epidermal growth factor receptor
Toni M. Brand et al.
SCIENCE SIGNALING (2017)
The receptor tyrosine kinase AXL mediates nuclear translocation of the epidermal growth factor receptor
Toni M. Brand et al.
SCIENCE SIGNALING (2017)
Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors
Yong Jia et al.
NATURE (2016)
Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition
Aaron N. Hata et al.
NATURE MEDICINE (2016)
Enrichr: a comprehensive gene set enrichment analysis web server 2016 update
Maxim V. Kuleshov et al.
NUCLEIC ACIDS RESEARCH (2016)
HGF/Met and FOXM1 form a positive feedback loop and render pancreatic cancer cells resistance to Met inhibition and aggressive phenotypes
J. Cui et al.
ONCOGENE (2016)
Mutational and network level mechanisms underlying resistance to anti-cancer kinase inhibitors
Maicol Mancini et al.
SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY (2016)
Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells
Michael Ramirez et al.
NATURE COMMUNICATIONS (2016)
FOXM1 confers resistance to gefitinib in lung adenocarcinoma via a MET/AKT-dependent positive feedback loop
Yu Wang et al.
ONCOTARGET (2016)
The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis
Yue-Lun Zhang et al.
Oncotarget (2016)
Combining three antibodies nullifies feedback-mediated resistance to erlotinib in lung cancer
Maicol Mancini et al.
SCIENCE SIGNALING (2015)
Combining three antibodies nullifies feedback-mediated resistance to erlotinib in lung cancer
Maicol Mancini et al.
SCIENCE SIGNALING (2015)
Massively Parallel Single-Cell RNA-Seq for Marker-Free Decomposition of Tissues into Cell Types
Diego Adhemar Jaitin et al.
SCIENCE (2014)
Dual Inhibition of EGFR with Afatinib and Cetuximab in Kinase Inhibitor-Resistant EGFR-Mutant Lung Cancer with and without T790M Mutations
Yelena Y. Janjigian et al.
CANCER DISCOVERY (2014)
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Michael I. Love et al.
GENOME BIOLOGY (2014)
Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool
Edward Y. Chen et al.
BMC BIOINFORMATICS (2013)
Marking and Measuring Single Microtubules by PRC1 and Kinesin-4
Radhika Subramanian et al.
CELL (2013)
Forkhead box proteins: tuning forks for transcriptional harmony
Eric W. -F. Lam et al.
NATURE REVIEWS CANCER (2013)
Single-cell mass cytometry adapted to measurements of the cell cycle
Gregory K. Behbehani et al.
CYTOMETRY PART A (2012)
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
Rafael Rosell et al.
LANCET ONCOLOGY (2012)
Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer
Zhenfeng Zhang et al.
NATURE GENETICS (2012)
Circumventing Cancer Drug Resistance in the Era of Personalized Medicine
Levi A. Garraway et al.
CANCER DISCOVERY (2012)
HER2 Amplification: A Potential Mechanism of Acquired Resistance to EGFR Inhibition in EGFR-Mutant Lung Cancers That Lack the Second-Site EGFRT790M Mutation
Ken Takezawa et al.
CANCER DISCOVERY (2012)
Phase I/II Trial of Cetuximab and Erlotinib in Patients with Lung Adenocarcinoma and Acquired Resistance to Erlotinib
Yelena Y. Janjigian et al.
CLINICAL CANCER RESEARCH (2011)
Mechanistic insights into the activation of oncogenic forms of EGF receptor
Zhihong Wang et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2011)
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
Tetsuya Mitsudomi et al.
LANCET ONCOLOGY (2010)
Combination antibody treatment down-regulates epidermal growth factor receptor by inhibiting endosomal recycling
Jamie B. Spangler et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Persistent elimination of ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies: Relevance of receptor endocytosis
Tsipi Ben-Kasus et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Derailed endocytosis: an emerging feature of cancer
Yaron Mosesson et al.
NATURE REVIEWS CANCER (2008)
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib
James Bean et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
Jeffrey A. Engelman et al.
SCIENCE (2007)
Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3
Natalia V. Sergina et al.
NATURE (2007)
FoxM1: At the crossroads of ageing and cancer
Jamila Laoukili et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2007)
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain
W Pao et al.
PLOS MEDICINE (2005)
EGF receptor gene mutations are common in lung cancers from never smokers and are associated with sensitivity of tumors to gefitinib and erlotinib
W Pao et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
EGFR mutations in lung cancer:: Correlation with clinical response to gefitinib therapy
JG Paez et al.
SCIENCE (2004)
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
TJ Lynch et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Sensitivity of non-small-cell lung cancer cell lines established from patients treated with prolonged infusions of paclitaxel
T Fujishita et al.
ONCOLOGY (2003)
Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways
WL Xia et al.
ONCOGENE (2002)
Activation of ErbB-2 via a hierarchical interaction between ErbB-2 and type I insulin-like growth factor receptor in mammary tumor cells
ME Balañá et al.
ONCOGENE (2001)
Cross-talk between epidermal growth factor receptor and c-Met signal pathways in transformed cells
MJ Jo et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
分享论文
